Cision PR Newswire

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings,...

Innovative Immunology Biotech Windward Bio Lists on Nasdaq

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- Windward Bio, a portfolio company of Qiming Venture...

WeFetch AI Corp. Is the New Name of GreenCore Solutions Corp.

gtinfetch.ai, WeFetch.ai's lead product, removes the guess from artificial intelligence (AI) shopping: the right...

China’s ETF Connect embraces the largest expansion in history as offshore investors’ appetite grows

14 ETFs under ChinaAMC are added, making it the largest fund company by total products included BEIJING, Jan. 19, 2026 /PRNewswire/ -- Offshore...

Harvest Global Investments Announces New CEO and Executive Appointments, Deepening Synergy with Parent Company Harvest Fund to Pioneer New Horizons in Cross-Border Investment

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Harvest Global Investments Limited ("HGI"), the international subsidiary of Harvest Fund Management, today announced a new round of...

Ageing, smoking, oral bacteria and genetic mutations linked to higher stomach cancer risk

Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of stomach cancer....

SHIMENG Supply Chain Management Launches A-Share IPO, Largest External Shareholder Shoucheng Holdings (0697.HK) Sees Investment Value Enter Realization Phase

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- SHIMENG SUPPLY CHAIN MANAGEMENT CO., LTD. ("SHIMENG"), an investee company of Shoucheng Holdings (0697.HK), has recently initiated...

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal...